Sermorelin carries theoretical risks of elevated cortisol and prolactin at higher doses, particularly in individuals with adrenal sensitivity or pre-existing endocrine imbalances
A DanishNorwegian cohort study , also covered by Verywell Health, suggested the risk may be roughly double for diabetic patients on semaglutide
Prevailing theories suggest incomplete FAO causes lipids (long-chain ACs, acyl-CoA, ceramide, diacylglycerol) to accumulate in the cytosol leading to disruption and inhibition of insulin signaling [24,39,60]
Treatment typically begins with a 0.25 mg weekly dose for four weeks as a starter dose for tolerability only, then increases to 0.5 mg once weekly for glycaemic control
Semaglutide is generally more cost-effective in long-term use because of its higher efficacy and less frequent dosing